Replies to post #397324 on Innovation Pharmaceuticals Inc (IPIX)

[frenchbroad]

Identify which of these are truth or illusion.
> Brilacidin has completed Phase 2 clinical trials for ABSSSI and Oral Mucositis and a Phase 2 Proof of Concept Ulcerative Proctitis trial. All of these trials reached success for primary endpoint and safety.
> Brilacidin has good published and peer-reviewed in vitro and in vivo research results performed in multiple independent laboratories and universities for anti-bacterial and anti-viral and anti-fungal and anti-inflammatory effects. More research continues.
> Brilacidin has received several research grants from USA government.
> Brilacidin has received 2 Fast Track and 1 Qualified Infectious Disease Product designations from USA FDA.
> Ipix has a development deal with EU partner AlfaSigma which can be worth USD$24 million plus 6% royalties. This deal is for only the small Ulcerative Proctitis market Brilacidin can maybe help.
> Ipix owns about 1/3 of a different company developing a new laser surgery treatment which may receive USA FDA marketing clearance in 2024. This other company already has USA FDA clearance for the laser component on the system plus a USA distribution partnership.
> On 6 April 2023 the USA stock market has a value for Ipix less than USD$10 million for all of these things together.
> Ipix is dead.

I will help. Only 1 is illusion.